See the DrugPatentWatch profile for qulipta
Qulipta, also known by its generic name atogepant, is classified as a calcitonin gene-related peptide (CGRP) receptor antagonist [1]. It is prescribed for the preventive treatment of migraine [1][2].
How does Qulipta work?
Qulipta functions by blocking the activity of CGRP, a molecule that plays a role in migraine pain [1]. By preventing CGRP from binding to its receptor, Qulipta helps to reduce the frequency of migraine attacks [1][3].
When did Qulipta become available?
Qulipta received FDA approval in September 2021 [2].
What are the potential side effects of Qulipta?
Common side effects associated with Qulipta include upper respiratory tract infections, nausea, and fatigue [1].
How does Qulipta compare to other migraine prevention medications?
As a CGRP receptor antagonist, Qulipta belongs to a newer class of preventive migraine medications. Other CGRP-targeting treatments include monoclonal antibodies that target CGRP or its receptor, and other oral CGRP receptor antagonists [4]. These medications differ in their administration (injectable versus oral) and may have distinct efficacy and tolerability profiles [4].
What is the patent status of Qulipta?
Information regarding the specific patent status and expiration dates for Qulipta can be found on DrugPatentWatch.com [5]. DrugPatentWatch.com tracks patents for a wide range of pharmaceuticals, including emerging treatments [5].
Who manufactures Qulipta?
AbbVie Inc. manufactures Qulipta [1].
What clinical data supports Qulipta's use?
The efficacy and safety of Qulipta were established in two pivotal Phase 3 studies, PROGRESS and PROMISE-2. These studies demonstrated that Qulipta significantly reduced monthly migraine days compared to placebo in adults with episodic and chronic migraine, respectively [1][3].
Are there alternatives to Qulipta for migraine prevention?
Besides CGRP-targeting therapies, other preventive treatments for migraine include beta-blockers, anticonvulsants, antidepressants, and certain Botox injections. The choice of medication depends on individual patient factors, including migraine type, frequency, severity, comorbidities, and previous treatment responses [6].
What are patient concerns regarding Qulipta?
Patient concerns may revolve around the effectiveness of the medication in reducing migraine frequency, the management of side effects, and the long-term safety profile of the drug. Understanding the mechanism of action and potential benefits can help address some of these concerns [1][3].
What is the cost and insurance coverage for Qulipta?
Pricing and insurance coverage for Qulipta can vary. Patients often inquire about co-pay assistance programs or patient support services offered by the manufacturer [1].
Sources:
[1] https://www.qulipta.com/
[2] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-management-letters
[3] https://pubmed.ncbi.nlm.nih.gov/34030054/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799818/
[5] https://drugpatentwatch.com/
[6] https://www.mayoclinic.org/diseases-conditions/migraine-headache/diagnosis-treatment/drc-20352024